The 18 most recent market catalysts affecting $CTVA, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 18, 2026
Corporate Catalyst
Neutral
Impact 55
Argus Research Reiterates Buy on Corteva, Maintains $91 Price Target
Argus Research analyst Alexandra Yates reiterated a 'Buy' rating for Corteva (CTVA) and maintained her $91 price target. This action signals continued analyst confidence in the com…
Sep 16, 2026
Corporate Catalyst
Bearish
Impact 55
BMO Capital Maintains Outperform on Corteva, Lowers Price Target to $95
BMO Capital analyst Joel Jackson maintained an 'Outperform' rating on Corteva (CTVA) but lowered the price target from $100 to $95. This action signals that while the analyst still…
Sep 16, 2026
Corporate Catalyst
Bearish
Impact 55
RBC Capital Reiterates Outperform on Corteva, Maintains $103 Price Target
RBC Capital analyst Arun Viswanathan reiterated an 'Outperform' rating and maintained a $103 price target for Corteva. This action signals continued confidence from a major financi…
Sep 15, 2026
Corporate Catalyst
Neutral
Impact 75
Corteva Sees FY2029 Sales $8.400B-$8.700B
Corteva's 8-K filing discloses its sales outlook for fiscal year 2029, projecting revenues in the range of $8.4 billion to $8.7 billion. This guidance is significant as it provides…
Sep 15, 2026
Corporate Catalyst
Bullish
Impact 65
Corteva Sees $300M Of Gross Productivity Benefits Across 2027-2029; Corteva Sees More Than $200M Of Net Cost Improvement Across 2027-2029, After Inflation And Tariff Offsets; Residual Inflation And Tariff Impacts Will Be Concentrated Mostly In 2027; Says Its Seed-Treatment Portfolio Is Now About $500M, Vs. About $400M Before Separation
Corteva's 8-K filing is a disclosure related to its Investor Day, where the company provided forward-looking statements regarding its operational efficiency and product portfolio. …
Sep 15, 2026
Corporate Catalyst
Neutral
Impact 75
Reported Earlier, Corteva Rejects State Attorneys General Allegations, Vows To Vigorously Defend Planned Corporate Separation
This headline signals a significant corporate catalyst for Corteva (CTVA) as it faces legal challenges to its planned corporate separation. The 'vigorous defense' implies potential…
Sep 9, 2026
Corporate Catalyst
Bullish
Impact 75
Corteva Announces Definitive Agreement To Form 50/50 Crop Protection Joint Venture With Globachem; Expects Close In Q4 2026
This joint venture represents a significant strategic move for Corteva, aiming to leverage Globachem's strengths for expanded market access and a broader product portfolio in crop …
Aug 18, 2026
Corporate Catalyst
Bearish
Impact 55
UBS Maintains Neutral on Corteva, Lowers Price Target to $85
UBS analyst Joshua Spector has adjusted Corteva's price target downwards from $89 to $85, while keeping a 'Neutral' rating. This action suggests a revised valuation perspective fro…
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 55
BMO Capital Maintains Outperform on Corteva, Raises Price Target to $100
BMO Capital analyst Joel Jackson maintained an 'Outperform' rating on Corteva and raised the price target from $95 to $100. This action signals continued confidence from a prominen…
Jul 31, 2026
Corporate Catalyst
Bearish
Impact 75
Corteva shares are trading lower after the company reported mixed Q2 financial results and raised its FY26 adjusted EPS guidance with its midpoint below estimates.
This headline indicates a significant corporate catalyst for Corteva. While raising long-term guidance might seem positive, the market is focusing on the immediate disappointment o…
Jul 30, 2026
Corporate Catalyst
Bearish
Impact 75
Corteva shares are trading lower after the company reported mixed Q2 financial results
The headline directly points to Corteva's Q2 financial results as the catalyst for its stock decline. 'Mixed' results often imply that while some metrics might have met or exceeded…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 75
Corteva Raises FY2026 Adj EPS Guidance from $3.45-$3.70 to $3.60-$3.80 vs $3.75 Est
Corteva (CTVA) announced an upward revision to its adjusted EPS guidance for fiscal year 2026, moving the range from $3.45-$3.70 to $3.60-$3.80. This update is significant as it in…
Jul 30, 2026
Corporate Catalyst
Neutral
Impact 75
Corteva Q2 Adj. EPS $2.30 Beats $2.22 Estimate, Sales $6.379B Miss $6.582B Estimate
Corteva's Q2 results are a significant corporate catalyst for the agricultural sector. The EPS beat suggests strong operational efficiency or favorable pricing, which could be a po…
Jul 28, 2026
Corporate Catalyst
Neutral
Impact 75
Watching Corteva; Hearing Zacks Surprise Trader Buys Stock
The headline indicates that Zacks Surprise Trader, a service known for identifying stocks with high earnings surprise potential, has bought Corteva stock. This is a significant sho…
Jul 23, 2026
Corporate Catalyst
Bullish
Impact 55
Oppenheimer Maintains Outperform on Corteva, Raises Price Target to $95
Oppenheimer analyst Kristen Owen has maintained an 'Outperform' rating on Corteva (CTVA) and raised the price target from $89 to $95. This indicates a positive outlook from a promi…
Jul 21, 2026
Corporate Catalyst
Bullish
Impact 55
RBC Capital Maintains Outperform on Corteva, Raises Price Target to $103
RBC Capital's analyst Arun Viswanathan maintained an 'Outperform' rating for Corteva (CTVA) and raised the price target from $97 to $103. This action signals continued analyst conf…
Jul 20, 2026
Corporate Catalyst
Bullish
Impact 55
B of A Securities Maintains Buy on Corteva, Raises Price Target to $96
B of A Securities analyst Steve Byrne maintained a 'Buy' rating on Corteva and raised the price target from $90 to $96. This action indicates an analyst's increased confidence in C…
Jul 14, 2026
Market Technicals
Bullish
Impact 55
Mizuho Maintains Outperform on Corteva, Raises Price Target to $97
Mizuho analyst John Roberts maintained an 'Outperform' rating on Corteva (CTVA) and raised the price target by $1 to $97. This action signals continued confidence from a prominent …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.